WO2010069951A1 - Oral formulations comprising omega polyenoic fatty acids in combination with natural or semi -synthetic statins - Google Patents
Oral formulations comprising omega polyenoic fatty acids in combination with natural or semi -synthetic statins Download PDFInfo
- Publication number
- WO2010069951A1 WO2010069951A1 PCT/EP2009/067175 EP2009067175W WO2010069951A1 WO 2010069951 A1 WO2010069951 A1 WO 2010069951A1 EP 2009067175 W EP2009067175 W EP 2009067175W WO 2010069951 A1 WO2010069951 A1 WO 2010069951A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fatty acids
- omega
- natural
- semi
- polyenoic fatty
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 51
- 235000014113 dietary fatty acids Nutrition 0.000 title claims abstract description 40
- 229930195729 fatty acid Natural products 0.000 title claims abstract description 40
- 239000000194 fatty acid Substances 0.000 title claims abstract description 40
- 150000004665 fatty acids Chemical class 0.000 title claims abstract description 39
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 title claims abstract description 26
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 title claims abstract description 25
- 238000009472 formulation Methods 0.000 title claims abstract description 24
- 238000000034 method Methods 0.000 claims abstract description 6
- 230000008569 process Effects 0.000 claims abstract description 6
- 235000016709 nutrition Nutrition 0.000 claims abstract description 5
- 238000002360 preparation method Methods 0.000 claims abstract description 5
- 239000002775 capsule Substances 0.000 claims description 29
- 240000007594 Oryza sativa Species 0.000 claims description 26
- 235000007164 Oryza sativa Nutrition 0.000 claims description 26
- 235000007189 Oryza longistaminata Nutrition 0.000 claims description 23
- 239000007888 film coating Substances 0.000 claims description 12
- 238000009501 film coating Methods 0.000 claims description 12
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 10
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 10
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims description 10
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 6
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 6
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 6
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 6
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 6
- 229930003427 Vitamin E Natural products 0.000 claims description 5
- 235000010323 ascorbic acid Nutrition 0.000 claims description 5
- 229960005070 ascorbic acid Drugs 0.000 claims description 5
- 239000011668 ascorbic acid Substances 0.000 claims description 5
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 5
- 235000019165 vitamin E Nutrition 0.000 claims description 5
- 229940046009 vitamin E Drugs 0.000 claims description 5
- 239000011709 vitamin E Substances 0.000 claims description 5
- 229960004844 lovastatin Drugs 0.000 claims description 4
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims description 4
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 3
- 229960001021 lactose monohydrate Drugs 0.000 claims description 3
- 239000002417 nutraceutical Substances 0.000 claims description 3
- 235000021436 nutraceutical agent Nutrition 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 3
- 240000002234 Allium sativum Species 0.000 claims description 2
- 244000019459 Cynara cardunculus Species 0.000 claims description 2
- 235000019106 Cynara scolymus Nutrition 0.000 claims description 2
- 240000006365 Vitis vinifera Species 0.000 claims description 2
- 235000014787 Vitis vinifera Nutrition 0.000 claims description 2
- 235000016520 artichoke thistle Nutrition 0.000 claims description 2
- 239000000284 extract Substances 0.000 claims description 2
- 235000004611 garlic Nutrition 0.000 claims description 2
- 235000002532 grape seed extract Nutrition 0.000 claims description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 2
- 235000013824 polyphenols Nutrition 0.000 claims description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 150000005846 sugar alcohols Polymers 0.000 claims description 2
- 235000015097 nutrients Nutrition 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 14
- 239000011248 coating agent Substances 0.000 description 11
- 238000000576 coating method Methods 0.000 description 11
- 239000007903 gelatin capsule Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 4
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 4
- 229940057059 monascus purpureus Drugs 0.000 description 4
- 238000002663 nebulization Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 244000113306 Monascus purpureus Species 0.000 description 3
- 235000002322 Monascus purpureus Nutrition 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 239000003570 air Substances 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 235000021323 fish oil Nutrition 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 229960002855 simvastatin Drugs 0.000 description 2
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- 108010033266 Lipoprotein(a) Proteins 0.000 description 1
- 102000057248 Lipoprotein(a) Human genes 0.000 description 1
- 102000003820 Lipoxygenases Human genes 0.000 description 1
- 108090000128 Lipoxygenases Proteins 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 230000002744 anti-aggregatory effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 235000021004 dietary regimen Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229930185723 monacolin Natural products 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 238000009160 phytotherapy Methods 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to the field of formulations containing omega polyenoic fatty acids in combination with natural or semi-synthetic statins.
- Omega polyenoic fatty acids are long chain polyunsaturated fatty acids with between
- omega-3-polyenoic fatty acids in which the first unsaturated bond is between the third and the fourth carbon atom, from the terminal methyl group
- omega-6-polyenoic fatty acids in which the first unsaturated bond is between the sixth and the seventh carbon atom
- omega-3-polyenoic fatty acids in which fish oil is rich, the most widespread are eicosapentaenoic acid, generally indicated with the acronym EPA, and docosahexaenoic acid, indicated with the acronym DHA.
- EPA eicosapentaenoic acid
- DHA docosahexaenoic acid
- omega polyenoic fatty acids compete with arachidonic acid for binding to the enzymes cyclooxygenase and lipoxygenase, causing a reduction in blood triglyceride levels; moreover, they have an anti-aggregation and antithrombotic action due to their effect of reducing thromboxane A2 synthesis; they promote vasodilation and increase bleeding time .
- omega polyenoic fatty acids are indicated in the prevention of recurrences after angioplasty surgery and for reducing angina attacks, as well as for treating hypertriglyceridemia, when combined with modified dietary regimens or also when the response to diets and other non-pharmacological measures alone has proved inadequate.
- omega polyenoic fatty acids fish oil esters
- statins such as simvastatin and other statins.
- Consumption of omega polyenoic fatty acids can allow cholesterol lowering drugs, such as statins (which can be of synthetic or natural origin) to function more effectively.
- the polyenoic fatty acids according to the invention are preferably chosen in the group consisting of omega-3-polyenoic fatty acids, omega-6-polyenoic fatty acids, and their mixtures, more preferably mixtures of omega-3-polyenoic fatty acids.
- Particularly preferred according to the invention are mixtures of omega-3- polyenoic fatty acids containing EPA and DHA in quantities between 20 - 98% by weight calculated on the total weight of the mixture, and preferably in quantities equal to at least 60% by weight.
- the ratio by weight of EPA and DHA is, for example, between 0.05 and 2.5, and preferably between 0.9 and 1.5.
- the term natural or semi-synthetic statins is intended as fermented red rice, garlic and artichoke extracts and polyphenols from vitis vinifera.
- fermented red rice having a content of Lovastatin and Monacolin K higher than 1.5% by weight.
- the fermented red rice is obtained from fermentation of the common cooking rice ⁇ Oryza sativa), by means of a particular yeast, called Monascus purpureus or red yeast .
- This rice which owes its name to its characteristic colour, is a conventional component of Chinese phytotherapy but is also widely known in the Western world for its valuable hypolipidemic effects.
- monacolin K stands out, as it reflects the chemical structure and pharmacological action of lovastatin (a drug belonging to the statin category).
- the monacolin K of red rice is capable of inhibiting HMG-CoA reductase, which represents a key enzyme in the biosynthesis of cholesterol.
- HMG-CoA reductase represents a key enzyme in the biosynthesis of cholesterol.
- fermented red rice is more effective with respect to the administration of equivalent dosages of lovastatin, proving that its properties reflect a combination of actions that cannot be attributed solely to monacolin K. Also for this reason, besides its well-documented hypolipidemizing activity, fermented red rice seems to reduce cardiovascular risk due to antiatheroschlerotic activities of other type (antinflammatory, vasodilating and reductive effect on lipoprotein A levels). Controlled fermentation in the laboratory can also slightly vary the composition of Monascus purpureus and allow the selection of strains rich in Monacolin K or other substances having particular pharmacological actions.
- Natural or semi-synthetic statins - preferably fermented red rice - are present in the formulation of the invention in the quantities permitted for nutraceutical formulations, in particular up to 3 mg.
- the two active principles - fatty acids on the one hand and one or more natural or semi-synthetic statins on the other - are kept isolated from each other inside a same dosage unit.
- the active principle present in the higher dosage i.e. the fatty acid
- the second active principle is uniformly distributed on the capsule.
- Vitamin E Ascorbic acid
- these components act as stabilizers for the formulation of the invention.
- the present formulations typically contain, inside the capsule, from 100 to 1 ,500 mg of fatty acids, preferably around 1 ,000 mg.
- Natural or semi-synthetic statins are applied to the capsule with one or more film- coating agents and possibly one or more inert substances, using appropriate solvents.
- One or more further film coatings without said active principles and comprising one or more appropriate film-coating agents, possibly in admixture with at least an inert subtance, can be applied to the filmed coating containing the second active principle.
- film-coating agents chosen among hydroxy propyl methylcellulose, polyvinylpyrrolidone, polyvinyl alcohol / polyethylene glycol copolymers, and their mixtures are preferred; while the possible inert substance is chosen among lactose monohydrate, polyalcohols and other substances permitted for products intended for particular nutritional uses.
- EXAMPLE 1 EXAMPLE 1
- 10,600 soft gelatin capsules were prepared, containing 500 mg of omega-3-polyenoic fatty acids per capsule with a minimum EPA-DHA content of 30%. These capsules were placed in a coating pan equipped with automatic spray, product and air inlet temperature control system and nebulized with a suspension having the following composition, in order to obtain a fermented red rice content of
- statins Fermented red rice 1.5% 2,375 g
- Nebulization pressure 0.5 bar
- the capsules obtained were film-coated with a solution having the following composition: Hydroxy propyl methylcellulose 109 g
- the film-coating process was performed setting the following operating parameter on the equipment:
- Nebulization pressure 1 bar Pump speed: 15-25 rpm
- the capsules were analyzed and packed in polythene bottles to perform a stability study at 25 °C and 60% relative humidity and at 40 °C and
- Example 1 In the same operating conditions described in Example 1 , a suspension, having the following composition, was nebulized onto 10,600 soft gelatin capsules containing approximately 500 mg of the mixture of fatty acids of Example 1 :
- the capsules obtained were film-coated in the same operating conditions described in Example 1 with a coating solution having the following composition: Hydroxy propyl methylcellulose 109 g
- the capsules were analyzed and packed in polythene bottles to perform a stability study at 25 °C and 60% relative humidity and at 40 °C and 75% relative humidity, and were found to have the same stability as the capsules of
- Example 1 with regard to the fermented red rice content.
- 10,600 soft gelatin capsules were prepared, containing 1000 mg of omega-3- polyenoic fatty acids per capsule with a minimum EPA-DHA content of 70%.
- Nebulization pressure 0.5 bar Pump speed: 15-25 rpm
- the capsules obtained were film-coated with a coating solution having the following composition:
- the film-coating process was performed by setting the following operating parameters on the equipment:
- the capsules were analyzed and packed in polythene bottles to perform a stability study at 25 °C and 60% relative humidity and at 40 °C and 75% relative humidity, and were found to have the same stability as the capsules of
- Example 2 In the same operating conditions described in Example 1 , 2,800 soft gelatin capsules, containing approximately 500 mg of mixture of fatty acids, were nebulized with a suspension having the following composition: Fermented red rice 1.5% 630 g
- the capsules obtained were film-coated in the same operating conditions described in Example 1 with a coating solution having the following composition:
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Botany (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
There are described formulations for nutritional use for the oral administration of a single dose containing omega polyenoic fatty acids, in combination with natural or semi-synthetic statins and possible other nutrients; also described is the process for preparation of stable formulations.
Description
ORAL FORMULATIONS COMPRISING OMEGA POLYENOIC FATTY ACIDS IN COMBINATION WITH NATURAL OR SEMI -SYNTHETI C STATINS
FIELD OF THE INVENTION The present invention relates to the field of formulations containing omega polyenoic fatty acids in combination with natural or semi-synthetic statins.
STATE OF THE ART
Omega polyenoic fatty acids are long chain polyunsaturated fatty acids with between
18 and 22 carbon atoms; among these, omega-3-polyenoic fatty acids, in which the first unsaturated bond is between the third and the fourth carbon atom, from the terminal methyl group, and omega-6-polyenoic fatty acids, in which the first unsaturated bond is between the sixth and the seventh carbon atom, are essential.
Among the omega-3-polyenoic fatty acids, in which fish oil is rich, the most widespread are eicosapentaenoic acid, generally indicated with the acronym EPA, and docosahexaenoic acid, indicated with the acronym DHA. Another important omega-3-polyenoic fatty acid, not of fish but of vegetable origin, is alpha-linolenic acid, indicated with the acronym ALA.
It has been widely proven that omega polyenoic fatty acids compete with arachidonic acid for binding to the enzymes cyclooxygenase and lipoxygenase, causing a reduction in blood triglyceride levels; moreover, they have an anti-aggregation and antithrombotic action due to their effect of reducing thromboxane A2 synthesis; they promote vasodilation and increase bleeding time .
Due to these valuable biological effects, omega polyenoic fatty acids are indicated in the prevention of recurrences after angioplasty surgery and for reducing angina attacks, as well as for treating hypertriglyceridemia, when combined with modified dietary regimens or also when the response to diets and other non-pharmacological measures alone has proved inadequate.
In the vast majority of cases food sources of omega polyenoic fatty acids are not in fact sufficient to achieve an adequate therapeutic or preventive response and to obtain an adequate source of daily administration these acids must be consumed in the form of pharmaceutical formulations or products intended for special nutritional uses, such as the one forming the subject matter of the present invention.
In the pharmaceutical field, omega polyenoic fatty acids (fish oil esters) are in general combined with synthetic statins, such as simvastatin and other statins. Consumption of omega polyenoic fatty acids can allow cholesterol lowering drugs, such as statins (which can be of synthetic or natural origin) to function more effectively. The patent application PCT/EP2007/056344 by the same applicant describes formulations for the oral administration of omega polyenoic fatty acids in combination with active principles incompatible therewith, including synthetic statins (for example simvastatin). However, it must be considered that synthetic statins are considered a true drug, while in many cases the use of products of natural origin is more indicated, as these can also be used in the production of dietary supplements.
To date no formulations are known that contain the two components (omega polyenoic fatty acids and natural or semi-synthetic statins) and to obtain the effective benefits of their combination, it is necessary to administer several formulations, each containing only one of the components, due to technical prejudices and difficulties in the preparation of a single dose containing an oily liquid component and a powder component incompatible therewith. The advantages of instead being able to provide a single formulation for the simultaneous oral administration of omega polyenoic fatty acids and natural statins, especially in terms of patient compliance, are evident and the need was therefore felt to provide a formulation of this type. SUMMARY OF THE INVENTION
There are described pharmaceutical formulations for oral administration comprising omega polyenoic fatty acids in combination with natural or semi-synthetic statins, their preparation methods and their use. DETAILED DESCRIPTION OF THE INVENTION
With the present invention, these problems are overcome through a non- pharmaceutical formulation for the oral administration of omega polyenoic fatty acids in combination with natural or semi-synthetic statins. The polyenoic fatty acids according to the invention are preferably chosen in the group consisting of omega-3-polyenoic fatty acids, omega-6-polyenoic fatty acids, and their mixtures, more preferably mixtures of omega-3-polyenoic fatty acids.
Particularly preferred according to the invention are mixtures of omega-3- polyenoic fatty acids containing EPA and DHA in quantities between 20 - 98% by weight calculated on the total weight of the mixture, and preferably in quantities equal to at least 60% by weight. In these mixtures the ratio by weight of EPA and DHA is, for example, between 0.05 and 2.5, and preferably between 0.9 and 1.5.
According to the invention, the term natural or semi-synthetic statins is intended as fermented red rice, garlic and artichoke extracts and polyphenols from vitis vinifera. Particularly preferred is fermented red rice having a content of Lovastatin and Monacolin K higher than 1.5% by weight. The fermented red rice is obtained from fermentation of the common cooking rice {Oryza sativa), by means of a particular yeast, called Monascus purpureus or red yeast . This rice, which owes its name to its characteristic colour, is a conventional component of Chinese phytotherapy but is also widely known in the Western world for its valuable hypolipidemic effects. The enormous scientific and economic interest surrounding red rice is linked to the presence of Monascus purpureus; during its fermenting activity, this yeast is in fact enriched by a group of substances, called monacolins, which have been scientifically associated with marked hypocholesterolemizing activity. Among these, monacolin K stands out, as it reflects the chemical structure and pharmacological action of lovastatin (a drug belonging to the statin category). Similarly to these pharmaceutical products, the monacolin K of red rice is capable of inhibiting HMG-CoA reductase, which represents a key enzyme in the biosynthesis of cholesterol. As its plasma levels depend above all on this biosynthetic pathway (and only to a lesser extent on diet): integration with fermented red rice has proved effective in normalizing total cholesterol, LDL cholesterol and triglyceride levels.
In this sense, fermented red rice is more effective with respect to the administration of equivalent dosages of lovastatin, proving that its properties reflect a combination of actions that cannot be attributed solely to monacolin K. Also for this reason, besides its well-documented hypolipidemizing activity, fermented red rice seems to reduce cardiovascular risk due to antiatheroschlerotic activities of other type (antinflammatory, vasodilating and reductive effect on lipoprotein A levels). Controlled fermentation in the laboratory can also slightly vary the composition of Monascus
purpureus and allow the selection of strains rich in Monacolin K or other substances having particular pharmacological actions.
Natural or semi-synthetic statins - preferably fermented red rice - are present in the formulation of the invention in the quantities permitted for nutraceutical formulations, in particular up to 3 mg.
Preferably, according to the invention, the two active principles - fatty acids on the one hand and one or more natural or semi-synthetic statins on the other - are kept isolated from each other inside a same dosage unit. Preferably, the active principle present in the higher dosage, i.e. the fatty acid, is encapsulated, in a soft or hard gelatin capsule, while the second active principle, possibly in combination with one or more other active principles, is uniformly distributed on the capsule.
Among the active principles as defined above we can, for example choose: Vitamin E, Ascorbic acid and their mixtures. Besides supplying a vitamin, these components act as stabilizers for the formulation of the invention.
According to the invention, the present formulations typically contain, inside the capsule, from 100 to 1 ,500 mg of fatty acids, preferably around 1 ,000 mg. Natural or semi-synthetic statins are applied to the capsule with one or more film- coating agents and possibly one or more inert substances, using appropriate solvents.
One or more further film coatings without said active principles and comprising one or more appropriate film-coating agents, possibly in admixture with at least an inert subtance, can be applied to the filmed coating containing the second active principle. Among the film-coating agents that can be used according to the invention, film-coating agents chosen among hydroxy propyl methylcellulose, polyvinylpyrrolidone, polyvinyl alcohol / polyethylene glycol copolymers, and their mixtures are preferred; while the possible inert substance is chosen among lactose monohydrate, polyalcohols and other substances permitted for products intended for particular nutritional uses. The following examples are given by way of non-limiting illustration of the invention. EXAMPLE 1
10,600 soft gelatin capsules were prepared, containing 500 mg of omega-3-polyenoic fatty acids per capsule with a minimum EPA-DHA content of 30%.
These capsules were placed in a coating pan equipped with automatic spray, product and air inlet temperature control system and nebulized with a suspension having the following composition, in order to obtain a fermented red rice content of
200 mg per capsule equal to 3 mg of statins: Fermented red rice 1.5% 2,375 g
Ascorbic acid 382 g
Vitamin E 191 g
Polyvinylpyrrolidone 687 g
Ethano 2,748 g Acetone 6,106 g
Processing was performed by setting the following operating parameters on the equipment:
Coating pan revolutions: 8 rpm
Inlet air temperature: 52 °C Nozzle: 1 mm hole
Nebulization pressure: 0.5 bar
Pump speed: 15-25 rpm
The capsules obtained were film-coated with a solution having the following composition: Hydroxy propyl methylcellulose 109 g
Acetone 930 g
Ethanol 930 g
Water 21 O g
The film-coating process was performed setting the following operating parameter on the equipment:
Coating pan revolutions: 8 rpm
Inlet air temperature: 45 °C
Nozzle: 1 mm hole
Nebulization pressure: 1 bar Pump speed: 15-25 rpm
At the end of the film-coating process and subsequent drying the capsules were analyzed and packed in polythene bottles
to perform a stability study at 25 °C and 60% relative humidity and at 40 °C and
75% relative humidity, obtaining the following results in relation to fermented red rice content:
25 °C 60% RH 40 °C 75% RH Time (0) 198.9 mg/capsule 198.9 mg/capsule
3 months: 206 mg/capsule 196.3 mg/capsule
EXAMPLE 2
In the same operating conditions described in Example 1 , a suspension, having the following composition, was nebulized onto 10,600 soft gelatin capsules containing approximately 500 mg of the mixture of fatty acids of Example 1 :
Fermented red rice 3% 1 ,18O g
Lactose monohydrate 1 ,18O g
Ascorbic acid 382 g
Vitamin E 191 g Polyvinylpyrrolidone 687 g
Ethanol 2,748 g
Acetone 6,106 g
The capsules obtained were film-coated in the same operating conditions described in Example 1 with a coating solution having the following composition: Hydroxy propyl methylcellulose 109 g
Acetone 930 g
Ethanol 930 g
Water 21 O g
The capsules were analyzed and packed in polythene bottles to perform a stability study at 25 °C and 60% relative humidity and at 40 °C and 75% relative humidity, and were found to have the same stability as the capsules of
Example 1 with regard to the fermented red rice content.
EXAMPLE 3
10,600 soft gelatin capsules were prepared, containing 1000 mg of omega-3- polyenoic fatty acids per capsule with a minimum EPA-DHA content of 70%.
These capsules were placed in a coating pan equipped with automatic spray, product and air inlet temperature control system and nebulized with a suspension having the
following composition in order to obtain a fermented red rice content of 200 mg per capsule equivalent to 3 mg of statins:
Fermented red rice 1.5% 2,375 g
Ascorbic acid 382 g Vitamin E 191 g
Polyvinylpyrrolidone 687 g
Ethanol 2,748 g
Acetone 6,106 g
Processing was performed by setting the following operating parameters on the equipment:
Coating pan revolutions: 8 rpm
Inlet air temperature: 52 °C
Nozzle: 1 mm hole
Nebulization pressure: 0.5 bar Pump speed: 15-25 rpm
The capsules obtained were film-coated with a coating solution having the following composition:
Hydroxy propyl methylcellulose 109 g
Acetone 930 g Ethanol 930 g
Water 21 O g
The film-coating process was performed by setting the following operating parameters on the equipment:
Coating pan revolutions: 8 rpm Inlet air temperature: 45 °C
Nozzle: 1 mm hole
Nebulization pressure: 1 bar
Pump speed: 15-25 rpm
The capsules were analyzed and packed in polythene bottles to perform a stability study at 25 °C and 60% relative humidity and at 40 °C and 75% relative humidity, and were found to have the same stability as the capsules of
Example 1 with regard to the fermented red rice content.
EXAMPLE 4
In the same operating conditions described in Example 1 , 2,800 soft gelatin capsules, containing approximately 500 mg of mixture of fatty acids, were nebulized with a suspension having the following composition: Fermented red rice 1.5% 630 g
Polyvinylpyrrolidone 189 g
Ethanol 2,220 g
Water 100 g
The capsules obtained were film-coated in the same operating conditions described in Example 1 with a coating solution having the following composition:
Hydroxy propyl methylcellulose 50 g
Acetone 425 g
Ethanol 425 g
Water 100 g The capsules were analyzed obtaining a fermented red rice content equal to 205 mg/capsule.
EXAMPLE 5
In the same operating conditions described in Example 4, 2,800 soft gelatin capsules, containing approximately 500 mg of the mixture of fatty acids, were nebulized with a suspension having the following composition:
Fermented red rice 1.5% 630 g
Polyvinyl alcohol / polyethylene glycol copolymer 280 g
Ethanol 1 ,260 g
Water 1 ,260 g The capsules obtained were film-coated in the same operating conditions and with the same coating solution as Example 4, obtaining at the end of the analytical tests a fermented red rice content equal to 200 mg/capsule.
Claims
1. Nutritional formulations for the oral administration of omega polyenoic fatty acids in combination with natural or semi-synthetic statins.
2. Nutritional formulations according to Claim 1 wherein said polyenoic fatty acids are chosen in the group consisting of: omega-3-polyenoic fatty acids, omega-6- polyenoic fatty acids, and their mixtures, preferably mixtures of omega-3- polyenoic fatty acids.
3. Formulations according to Claim 2 wherein said mixtures of omega-3-polyenoic fatty acids comprise EPA and DHA in quantities between 20 - 98% by weight calculated on the total weight of the mixture.
4. Formulations according to claims 1 - 3 wherein said natural or semi-synthetic statins are chosen in the group consisting of: fermented red rice, garlic and artichoke extracts and polyphenols from vitis vinifera..
5. Formulations according to Claim 4 wherein said statins are fermented red rice having a content of Lovastatin and Monacolin K higher than 1.5% by weight.
6. Formulations according to claims 4 and 5 wherein said natural or semi-synthetic statins are present in the quantities permitted for nutraceutical formulations, in particular up to 3 mg.
7. Formulations according to claims 1 - 6 wherein said omega polyenoic fatty acids and said natural or semi-synthetic statins are kept isolated from each other in a single dosage unit.
8. Formulations according to claim 7 wherein the fatty acid is encapsulated while the second active principle, possibly in combination with one or more other active principles, is uniformly distributed on said capsule.
9. Formulations according to claim 7 wherein said other active principles are chosen among: Vitamin E, ascorbic acid and their mixtures.
10. Process for the preparation of formulations according to claims 1 -9 wherein natural or semi-synthetic statins are applied to the capsule with one or more film- coating agents and possibly one or more inert substances, using appropriate solvents, and one or more further film coatings, without said active principles but containing one or more appropriate film-coating agents, possibly in admixture with at least an inert substance, are possibly applied to the capsule thus obtained.
1. Process according to claim 10 wherein said film-coating agents are chosen among hydroxy propyl methylcellulose, polyvinylpyrrolidone, polyvinyl alcohol / polyethylene glycol copolymers, and their mixtures; while the possible inert substance is chosen among lactose monohydrate, polyalcohols and other substances used for the preparation of nutraceuticals.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITFI2008A000243 | 2008-12-15 | ||
IT000243A ITFI20080243A1 (en) | 2008-12-15 | 2008-12-15 | FORMULATIONS FOR ORAL ADMINISTRATION OF OMEGA POLIENOIC FATTY ACIDS IN COMBINATION WITH NATURAL OR SEMI-SYNTHETIC STATINES. |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010069951A1 true WO2010069951A1 (en) | 2010-06-24 |
Family
ID=40600075
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2009/067175 WO2010069951A1 (en) | 2008-12-15 | 2009-12-15 | Oral formulations comprising omega polyenoic fatty acids in combination with natural or semi -synthetic statins |
Country Status (2)
Country | Link |
---|---|
IT (1) | ITFI20080243A1 (en) |
WO (1) | WO2010069951A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2506848A1 (en) * | 2009-12-03 | 2012-10-10 | Joar Opheim | Substances for reducing occurrence of major cardiac events comprising red yeast rice extract and omega-3 polyunsaturated fatty acid or derivative thereof |
US20140010872A1 (en) * | 2011-03-23 | 2014-01-09 | Hanmi Pharm. Co., Ltd. | Oral complex composition comprising omega-3 fatty acid ester and hmg-coa reductase inhibitor |
WO2014153567A3 (en) * | 2013-03-05 | 2015-06-04 | Innovative Environmental Technologies, Inc. | Inhibition of methane production during anaerobic reductive dechlorination |
EP2853263A4 (en) * | 2012-05-22 | 2016-01-13 | Kuhnil Pharm Co Ltd | Multilayer coating form of orally administered pharmaceutical composition containing omega-3 fatty acid or alkyl ester thereof and statin based drug |
US9492545B2 (en) | 2012-05-07 | 2016-11-15 | Omthera Pharmaceuticals Inc. | Compositions of statins and omega-3 fatty acids |
Citations (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002043659A2 (en) * | 2000-11-29 | 2002-06-06 | Smithkline Beecham Corporation | Composition containing statins and calcium for improved cardiovascular health |
WO2002100394A1 (en) * | 2001-06-12 | 2002-12-19 | Galephar M/F | Oral pharmaceutical composition containing a statin derivative |
WO2004058281A1 (en) * | 2002-12-24 | 2004-07-15 | Nutrinova Nutrition Specialties & Food Ingedients Gmbh | Cholesterol-reducing agent containing an n-3 fatty acid |
WO2006013602A1 (en) * | 2004-08-03 | 2006-02-09 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Composition containing statins and omega-3 fatty acids |
WO2006016357A1 (en) * | 2004-08-09 | 2006-02-16 | Enzymotec Ltd. | Food products for diabetics |
WO2006021293A1 (en) * | 2004-08-23 | 2006-03-02 | Unilever N.V. | Composition comprising statin |
WO2006096806A2 (en) * | 2005-03-08 | 2006-09-14 | Reliant Pharmaceutiacals, Inc. | Treatment with statin and omega-3 fatty acids and a combination product thereof |
WO2006132879A2 (en) * | 2005-06-03 | 2006-12-14 | Soft Gel Technologies, Inc. | Soft gel capsules containing polymethoxylated flavones and palm oil tocotrienols |
WO2007019373A2 (en) * | 2005-08-04 | 2007-02-15 | Transform Pharmaceuticals, Inc. | Novel formulations comprising fenofibrate and a statin, and related methods of treatment |
EP1803440A1 (en) * | 2004-10-19 | 2007-07-04 | GP Pharm S.A. | Pharmaceutical formulation comprising microcapusles of statins suspended in alkyl esters of polyunsaturated fatty acids (pufa) |
WO2007103557A2 (en) * | 2006-03-09 | 2007-09-13 | Reliant Pharmaceuticals, Inc. | Coating capsules with active pharmaceutical ingredients |
CN101091708A (en) * | 2006-06-22 | 2007-12-26 | 沈阳东宇药业有限公司 | Composition for reducing blood fat, and preparation method |
WO2008000731A2 (en) * | 2006-06-26 | 2008-01-03 | Valpharma S.A. | Pharmaceutical composition for the oral administration of omega polyenoic fatty acids |
WO2008146016A2 (en) * | 2007-05-31 | 2008-12-04 | Omegatri A/S | Cyclodextrins for administering fatty acids in tablets |
US20080299187A1 (en) * | 2007-06-01 | 2008-12-04 | Joar Opheim | Substances for Reducing Occurence of Major Cardiac Events in Humans |
WO2009032699A1 (en) * | 2007-08-29 | 2009-03-12 | Drugtech Corporation | Anti-proliferative combinations |
WO2009059717A2 (en) * | 2007-11-08 | 2009-05-14 | Iervant Zarmanian | Pharmaceutical compositions containing statins and omega-3 fatty acids derivatives and their solid formulations for oral use |
WO2009087938A1 (en) * | 2008-01-10 | 2009-07-16 | Takeda Pharmaceutical Company Limited | Capsule formulation |
-
2008
- 2008-12-15 IT IT000243A patent/ITFI20080243A1/en unknown
-
2009
- 2009-12-15 WO PCT/EP2009/067175 patent/WO2010069951A1/en active Application Filing
Patent Citations (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002043659A2 (en) * | 2000-11-29 | 2002-06-06 | Smithkline Beecham Corporation | Composition containing statins and calcium for improved cardiovascular health |
WO2002100394A1 (en) * | 2001-06-12 | 2002-12-19 | Galephar M/F | Oral pharmaceutical composition containing a statin derivative |
WO2004058281A1 (en) * | 2002-12-24 | 2004-07-15 | Nutrinova Nutrition Specialties & Food Ingedients Gmbh | Cholesterol-reducing agent containing an n-3 fatty acid |
WO2006013602A1 (en) * | 2004-08-03 | 2006-02-09 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Composition containing statins and omega-3 fatty acids |
WO2006016357A1 (en) * | 2004-08-09 | 2006-02-16 | Enzymotec Ltd. | Food products for diabetics |
WO2006021293A1 (en) * | 2004-08-23 | 2006-03-02 | Unilever N.V. | Composition comprising statin |
EP1803440A1 (en) * | 2004-10-19 | 2007-07-04 | GP Pharm S.A. | Pharmaceutical formulation comprising microcapusles of statins suspended in alkyl esters of polyunsaturated fatty acids (pufa) |
WO2006096806A2 (en) * | 2005-03-08 | 2006-09-14 | Reliant Pharmaceutiacals, Inc. | Treatment with statin and omega-3 fatty acids and a combination product thereof |
WO2006132879A2 (en) * | 2005-06-03 | 2006-12-14 | Soft Gel Technologies, Inc. | Soft gel capsules containing polymethoxylated flavones and palm oil tocotrienols |
WO2007019373A2 (en) * | 2005-08-04 | 2007-02-15 | Transform Pharmaceuticals, Inc. | Novel formulations comprising fenofibrate and a statin, and related methods of treatment |
WO2007103557A2 (en) * | 2006-03-09 | 2007-09-13 | Reliant Pharmaceuticals, Inc. | Coating capsules with active pharmaceutical ingredients |
CN101091708A (en) * | 2006-06-22 | 2007-12-26 | 沈阳东宇药业有限公司 | Composition for reducing blood fat, and preparation method |
WO2008000731A2 (en) * | 2006-06-26 | 2008-01-03 | Valpharma S.A. | Pharmaceutical composition for the oral administration of omega polyenoic fatty acids |
WO2008146016A2 (en) * | 2007-05-31 | 2008-12-04 | Omegatri A/S | Cyclodextrins for administering fatty acids in tablets |
US20080299187A1 (en) * | 2007-06-01 | 2008-12-04 | Joar Opheim | Substances for Reducing Occurence of Major Cardiac Events in Humans |
WO2009032699A1 (en) * | 2007-08-29 | 2009-03-12 | Drugtech Corporation | Anti-proliferative combinations |
WO2009059717A2 (en) * | 2007-11-08 | 2009-05-14 | Iervant Zarmanian | Pharmaceutical compositions containing statins and omega-3 fatty acids derivatives and their solid formulations for oral use |
WO2009087938A1 (en) * | 2008-01-10 | 2009-07-16 | Takeda Pharmaceutical Company Limited | Capsule formulation |
Non-Patent Citations (3)
Title |
---|
ANONYMOUS: "Statin", WIKIPEDIA, THE FREE ENCYCLOPEDIA, 4 May 2009 (2009-05-04), XP002527461, Retrieved from the Internet <URL:http://en.wikipedia.org/wiki/Statin> [retrieved on 20090512] * |
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 2008, XP002527431, retrieved from STN Database accession no. 2008:1630 * |
DATABASE WPI Week 200949, Derwent World Patents Index; AN 2009-L52520, XP002574670 * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10596121B2 (en) | 2007-06-01 | 2020-03-24 | Nordic Naturals, Inc. | Substances for reducing occurrence of major cardiac events comprising red yeast rice extract and omega-3 polyunsaturated fatty acid or derivative thereof |
US11406602B2 (en) | 2007-06-01 | 2022-08-09 | Nordic Naturals, Inc. | Substances for reducing occurrence of major cardiac events comprising red yeast rice extract and omega-3 polyunsaturated fatty acid or derivative thereof |
EP2506848A1 (en) * | 2009-12-03 | 2012-10-10 | Joar Opheim | Substances for reducing occurrence of major cardiac events comprising red yeast rice extract and omega-3 polyunsaturated fatty acid or derivative thereof |
EP2506848A4 (en) * | 2009-12-03 | 2013-07-31 | Joar Opheim | Substances for reducing occurrence of major cardiac events comprising red yeast rice extract and omega-3 polyunsaturated fatty acid or derivative thereof |
AU2010326054B2 (en) * | 2009-12-03 | 2015-02-05 | Joar Opheim | Substances for reducing occurrence of major cardiac events comprising red yeast rice and omega-3 polyunsaturated fatty acid or derivative thereof |
US20140010872A1 (en) * | 2011-03-23 | 2014-01-09 | Hanmi Pharm. Co., Ltd. | Oral complex composition comprising omega-3 fatty acid ester and hmg-coa reductase inhibitor |
US9492545B2 (en) | 2012-05-07 | 2016-11-15 | Omthera Pharmaceuticals Inc. | Compositions of statins and omega-3 fatty acids |
EP2853263A4 (en) * | 2012-05-22 | 2016-01-13 | Kuhnil Pharm Co Ltd | Multilayer coating form of orally administered pharmaceutical composition containing omega-3 fatty acid or alkyl ester thereof and statin based drug |
US9320718B2 (en) | 2012-05-22 | 2016-04-26 | Kuhnil Pharm. Co., Ltd. | Multilayer coating form of orally administered pharmaceutical composition containing omega-3 fatty acid or alkyl ester thereof and statin based drug |
WO2014153567A3 (en) * | 2013-03-05 | 2015-06-04 | Innovative Environmental Technologies, Inc. | Inhibition of methane production during anaerobic reductive dechlorination |
Also Published As
Publication number | Publication date |
---|---|
ITFI20080243A1 (en) | 2010-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Scicchitano et al. | Nutraceuticals and dyslipidaemia: beyond the common therapeutics | |
Trox et al. | Bioactive compounds in cashew nut (Anacardium occidentale L.) kernels: effect of different shelling methods | |
Maeda et al. | Seaweed carotenoid, fucoxanthin, as a multi-functional nutrient. | |
Kamal-Eldin et al. | Sesame seed lignans: potent physiological modulators and possible ingredients in functional foods & nutraceuticals | |
CA2640414C (en) | Combinations of botanical extracts for promoting cardiovascular health | |
US20120219619A1 (en) | Substances for reducing occurrence of major cardiac events in humans | |
US8507466B2 (en) | Oils enriched with diacylglycerols and phytosterol esters and unit dosage forms thereof for use in therapy | |
US20220265749A1 (en) | Preparation comprising omega-3 fatty acid salts and extracts of gum resins from boswellia species | |
KR101791278B1 (en) | Substances for reducing occurrence of major cardiac events comprising red yeast rice extract and omega-3 polyunsaturated fatty acid or derivative thereof | |
WO2010069951A1 (en) | Oral formulations comprising omega polyenoic fatty acids in combination with natural or semi -synthetic statins | |
WO2008000731A2 (en) | Pharmaceutical composition for the oral administration of omega polyenoic fatty acids | |
Zou et al. | Silkworm pupae oil exerts hypercholesterolemic and antioxidant effects in high‐cholesterol diet‐fed rats | |
NZ541887A (en) | Oils enriched with diacylglycerols and phytosterol esters for use in the reduction of cholesterol and triglycerides | |
JP2010100545A (en) | Activation enhancer of nuclear receptor and/or transcription factor | |
Sut et al. | Food-derived nutraceuticals for hypercholesterolemia management, mode of action and active ingredients. | |
da Mata et al. | Different biological activities (antimicrobial, antitumoral, and antioxidant activities) of grape seed oil | |
WO2019026067A1 (en) | Extracts of nannochloropsis microalgae and their uses | |
Yazawa | Recent development of health foods enriched with DHA, EPA and DPA in Japan | |
Tsoupras et al. | Bioactive Metabolites from Fungi with Anti-Inflammatory and Antithrombotic Properties: Current Status and Future Perspectives for Drug Development | |
Yang et al. | A systematic, updated review of Xuezhikang, a domestically developed lipid-lowering drug, in the application of cardiovascular diseases | |
Manosroi et al. | In vitro immunostimulating activity of the dried sap from fermented thai rice on human and murine neutrophils | |
CA2676583C (en) | Composition comprising red yeast rice and an omega-3 polyunsaturated fatty acid | |
Zafar et al. | Herbal Seeds for Lowering Low Density Lipoprotein Cholesterol and To Increase High Density Lipoprotein Cholesterol | |
Houston | Nutrition and Nutritional Supplements in the Management of Dyslipidemia—Part 2 | |
劉少凱 | Dietary Effect of Squalene and Farnesol on the Lipid Metabolism of Obese/diabetes KK-Ay Mice and Wild-type C57BL/6J Mice |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09801432 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 09801432 Country of ref document: EP Kind code of ref document: A1 |